Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Actinium Pharmaceuticals, Inc. (Delaware) Common Stock (NY:ATNM)

1.210 -0.040 (-3.20%)
Official Closing Price Updated: 6:30 PM EDT, Apr 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Actinium Pharmaceuticals, Inc. (Delaware) Common Stock

< Previous 1 2 3 4 Next >
High-Risk, High-Reward: Little-Known Biotech Stock ATNM Could Soar on Breakthrough Cancer Treatment
ATNM stock offers moonshot or crash-landing possibilities as Actinium Pharmaceuticals works relentlessly to advance life-changing treatments. 
Via InvestorPlace
Actinium Pharmaceuticals (NYSE AMERICAN: ATNM) launches strategic initiative focused on the manufacture of the highly sought after medical isotope Actinium-225 (Ac-225)
Via AB Newswire
Topics Intellectual Property
Exposures Intellectual Property
7 Biotech Penny Stocks on the Verge of Clinical Trial Victory
Biotech penny stocks represent one heckuva risk. However, if the stars align, you could be talking some serious money. 
Via InvestorPlace
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
Actinium Pharma – Pivotal Results From Key New Drug In The Fight Against Cancer
Sandesh Seth, CEO & Chairman of the Board of Actinium Pharmaceuticals (NASDAQ: ATNM), was recently a guest on Benzinga’s All-Access. 
Via Benzinga
(ATNM) - Analyzing Actinium Pharmaceuticals's Short Interest
Via Benzinga
Actinium Shares Are Trading Higher After Positive Data From Acute Myeloid Leukemia Trial
Via Benzinga
With Upcoming Pivotal Data, Analyst Sees 145% Upside In Actinium
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 6, 2023
Via Benzinga
Actinium Pharma Cratered 37% Over Two Days — Here's Why, According To CEO Sandesh Seth
Actinium CEO Sandesh Seth says the tumble this week had little to do with clinical data. 
Via Investor's Business Daily
Global Market for Acute Myeloid Leukemia Expected to Reach $3.2 Billion By 2029
EQNX::TICKER_START (NYSE:ATNM),(NASDAQ:AZN),(NYSE:BMY),(NYSE:AMAM),(NYSE:GSK) EQNX::TICKER_END 
Via FinancialNewsMedia
Actinium Announces Positive Full Data Results From the Pivotal Phase 3 SIERRA Trial in Patients with Active, Relapsed or Refractory Acute Myeloid Leukemia
– Iomab-B met the primary endpoint of durable Complete Remission (dCR) of 6-months following initial complete remission after BMT with high statistical significance (p-value of <0.0001), 22% of... 
Via FinancialNewsMedia
Benzinga's Top Ratings Upgrades, Downgrades For February 21, 2023
Via Benzinga
What's Going On With Actinium Pharmaceuticals Stock?
Actinium Pharmaceuticals Inc (AMEX:ATNM) shares are trading higher Tuesday after the company announced full data results from the pivotal Phase 3 SIERRA trial in patients with active, relapsed or... 
Via Benzinga
Why Owlet Shares Are Trading Higher By Over 45%; Here Are 20 Stocks Moving Premarket
Gainers Troika Media Group Inc (NASDAQ: TRKA) shares rose 65.9% to $0.37 in pre-market trading after dropping 4% on Friday. 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
It's time to start another day of trading with a breakdown of the biggest pre-market stock movers traders need to know about for Tuesday! 
Via InvestorPlace
Actinium Pharmaceuticals’ Shares Stay Bullish Ahead Of Expected Topline Phase 3 Data Release In Q4 ($ATNM)
Via AB Newswire
Actinium Pharmaceuticals’ Shares Rally Ahead Of Topline Phase 3 Data Release; Update Expected By Year’s End ($ATNM)
Via AB Newswire
Why American Eagle Outfitters Shares Climbed Over 18%; Here Are 78 Biggest Movers From Yesterday
Gainers Cosmos Holdings Inc. (NASDAQ: COSM) jumped 86.9% to close at $0.3275 on Tuesday after jumping 21% on Monday. Cosmos Health agreed to sell its Sky Premium Life Luxury food supplement brand on... 
Via Benzinga
Dollar Tree, Dycom Industries, Chico's FAS And Other Big Losers From Tuesday
U.S. stocks closed higher on Tuesday, with the Dow Jones gaining around 400 points. Here is the list of some big stocks recording losses in the previous session. 
Via Benzinga
4 Analysts Have This to Say About Actinium Pharmaceuticals
Over the past 3 months, 4 analysts have published their opinion on Actinium Pharmaceuticals (AMEX:ATNM) stock. These analysts are typically employed by large Wall Street banks and tasked with... 
Via Benzinga
Why Is Getty Images (GETY) Stock Up 33% Today?
Getty Images (GETY) stock is rising higher on Monday with heavy trading despite a lack of news concerning the company today. 
Via InvestorPlace
PERF Stock Soars 21% on First Trading Day
Perfect (PERF) stock is taking off on Monday as investors pump shares higher on their first day of trading after a SPAC merger. 
Via InvestorPlace
Why Dollar Tree Shares Are Trading Lower By 10%? Here Are 53 Stocks Moving In Tuesday's Mid-Day Session
Gainers Palisade Bio, Inc. (NASDAQ: PALI) shares jumped 99.1% to $4.42 after the company announced the FDA granted Fast Track designation to LB1148 for the acceleration of time to return of bowel... 
Via Benzinga
Actinium (ATNM) Stock Pops on Positive Trial Results
Actinium Pharmaceuticals (ATNM) stock is gaining on Monday after posting positive results from a Phase 3 clinical trial. 
Via InvestorPlace
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
Welcome back and get ready for another week of trading as we break down the biggest pre-market stock movers for Monday morning! 
Via InvestorPlace
Why Sonnet BioTherapeutics Shares Surged Over 66%; Here Are 63 Biggest Movers From Yesterday
Gainers Sonnet BioTherapeutics Holdings, Inc. (NASDAQ: SONN) climbed 66.4% to close at $1.93 on Monday after the company announced an agreement with Janssen for the evaluation of three Sonnet product... 
Via Benzinga
Actinium Pharmaceuticals’ Q4 Phase 3 Trial Updates Could Make Expected Milestones 2023 Catalysts ($ATNM)
Via AB Newswire
Actinium Pharmaceuticals’ Investor Update Puts Clinical Milestones And Potential Catalysts In The Crosshairs ($ATNM)
Via AB Newswire
Benzinga's Top Ratings Upgrades, Downgrades For September 8, 2022
  
Via Benzinga
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.